禁毒局因阻碍大麻研究而面临批评, 被控将繁文缛节排在公共卫生之上。 DEA faces criticism for blocking cannabis research, accused of prioritizing red tape over public health.

缉毒局因处理大麻研究申请,被控系统腐败和监管疏忽,正面临批评。 The DEA is facing criticism for its handling of cannabis research applications, accused of systemic corruption and regulatory negligence. 尽管该机构的任务是确保为医疗需要提供受管制物质,但它阻止了MMJ生物制药公司等公司的临床试验,使患有Huntington病和多发性硬化症等疾病的患者得不到可能的治疗。 Despite its mission to ensure controlled substances are available for medical needs, the agency has blocked clinical trials by companies like MMJ BioPharma, leaving patients with conditions like Huntington's disease and Multiple Sclerosis without potential treatments. 内部声明表明,禁毒局将官僚主义繁文缛节置于科学进步和公共卫生之上。 Internal statements suggest the DEA prioritizes bureaucratic red tape over scientific progress and public health.